Low levels of C-peptide have clinical significance for established Type 1 diabetes

Diabetic Medicine

Volumn 32, Issue 10, 2015, Pages 1346-1353

  Kuhtreiber, W M ^a   Washer, S L L ^a   Hsu, E ^a   Zhao, M ^a   Reinhold, P ^a   Burger, D ^a   Zheng, H ^a   Faustman, D L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; C PEPTIDE; GLUCOSE; 1,5-ANHYDROGLUCITOL; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOOT ULCER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; ONSET AGE; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 1; METABOLISM; MIDDLE AGED; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CROSS-SECTIONAL STUDIES; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84941886212     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12850     Document Type: Article

References (30)

1. Genuth SM. The case for blood glucose control. Advances Intern Med 1995; 40: 573-623.
2. DCCT.Research.Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comments]. N Engl J Med 1993; 329: 977-986.
3. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836.
4. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39: 625-640.
5. Sorensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, Hertel NT etal. Residual beta-Cell function 3-6years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care 2013; 36: 3454-3459.
6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR etal. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
7. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012; 35: 465-470.
8. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ etal. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014; 57: 187-191.
9. Faustman DL. Why were we wrong for so long? The pancreas of type 1 diabetic patients commonly functions for decades. Diabetologia 2014; 57: 1-3.
10. Eisenbarth GS. Type I diabetes mellitus: A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
11. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1): S5-S13.
12. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995; 18: 517-522.
13. DCCT. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
14. Giordano C, Galluzzo A, Panto F, Caruso C, Bompiani G. Prevalence of residual B-cell function related to age at onet and genetic profile in newly diagnosed type 1 diabetics. Acta Diabetologica 1987; 24: 317-323.
15. Lachin JM, McGee P, Palmer JP, Group DER. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63: 739-748.
16. Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbol I. Prevalence of residual beta-cell function in insulin-dependent in relation to age at onset and duration of diabetes. Diabetes 1978; 27(Suppl. 1): 262-264.
17. Ludvigsson J, Carlsson A, Deli A, Forsander G, Ivarsson SA, Kockum I etal. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 2013; 100: 203-209.
18. Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C etal. Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 2014; 16: 262-267.
19. Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G etal. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PloS One 2012; 7: e41756.
20. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H etal. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
21. McGee P, Steffes M, Nowicki M, Bayless M, Gubitosi-Klug R, Cleary P etal. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabet Med 2014; 31: 1264-1268.
22. Vantyghem MC, Raverdy V, Balavoine AS, Defrance F, Caiazzo R, Arnalsteen L etal. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3). J Clin Endocrinol Metab 2012; 97: E2078-E2083.
23. Yamanouchi T, Kawasaki T, Yoshimura T, Inoue T, Koshibu E, Ogata N etal. Relationship between serum 1, 5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care 1998; 21: 619-624.
24. Kim WJ, Park CY, Park SE, Rhee EJ, Lee WY, Oh KW etal. Serum 1, 5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet Med 2012; 29: 1184-1190.
25. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T. Serum 1, 5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 2011; 216: 477-483.
26. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care 2012; 35: 2265-2270.
27. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S etal. 1, 5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.
28. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M etal. Association of 1, 5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008; 31: 1534-1535.
29. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE etal. Prevalence of Detectable C-peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. Diabetes Care 2015; 38: 476-481.
30. Lowe WL Jr, Bain JR. "Prediction is very hard, especially about the future": new biomarkers for type 2 diabetes? Diabetes 2013; 62: 1384-1385.